MK-4827 (Tosylate), 10 mg

A selective small-molecule inhibitor of PARP1 and PARP2, MK-4827 tosylate is supplied by STEMCELL Technologies as a 10 mg vial for cancer biology research. The compound, the tosylate salt of the clinical-stage PARP inhibitor niraparib, is widely used in synthetic lethality studies involving BRCA-deficient and homologous recombination-deficient tumor models including ovarian, breast, and prostate cancer cell lines.

This research-grade compound arrives as a lyophilized solid and is typically reconstituted in DMSO to prepare stock concentrations for in vitro cell-based assays. Researchers employ MK-4827 tosylate to interrogate poly(ADP-ribosyl)ation signaling, sensitize tumor cells to DNA-damaging agents, and evaluate combination strategies with temozolomide, platinum agents, or ionizing radiation in cell culture workflows.

Storage at -20 °C is recommended to preserve compound integrity across multiple freeze-thaw cycles, and aliquoting upon first use is advised to minimize hydrolytic degradation. The tosylate counterion improves aqueous solubility relative to the free base, supporting consistent dosing in cytotoxicity, clonogenic survival, and DNA repair reporter assays. For research use only.